Opinion|Videos|March 14, 2025
CAR T-Cell Therapy for B-ALL: Roles Within the Multidisciplinary Care Team
Experts discuss their distinct roles in patient eligibility, management, and follow-up for chimeric antigen receptor (CAR) T-cell therapy treatment in adult patients with precursor B-cell acute lymphoblastic leukemia (B-ALL), focusing on assessment, treatment planning, and ongoing care.
Advertisement
Video content above is prompted by the following:
Please briefly describe your distinct roles with patient eligibility for CAR T-cell therapy treatment, management, and follow-up in adult patients with precursor B-ALL.
Advertisement
Related to this article
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
Roswell Park Comprehensive Cancer Center recognized members of its clinical, research and healthcare teams during the second annual Excellence Awards.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
5